Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Trial of CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions Delivered With the Surefire Infusion System (SIS) for CEA-Expressing Liver Metastases or Pancreas Cancer

Trial Profile

Phase Ib Trial of CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions Delivered With the Surefire Infusion System (SIS) for CEA-Expressing Liver Metastases or Pancreas Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs CAR-T CEA therapy (Primary)
  • Indications Adenocarcinoma; Liver metastases; Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms HITM-SURE
  • Most Recent Events

    • 06 Nov 2018 Results presented in a Sorrento Therapeutics media release.
    • 06 Nov 2018 According to a Sorrento Therapeutics media release, preliminary data from the study will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2018.
    • 14 Jun 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top